The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...
The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...
The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...
On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody and topoisomerase inhibitor con | Cancer ...
Growth hormone treatment is a safe and effective therapy that’s often used to treat children and adults with a deficiency in human growth ... it’s also been FDA-approved to support individuals ...
Human chorionic gonadotropin ... The hCG diet involves taking a hormone made in the body during pregnancy and following a very low-calorie diet. hCG isn’t FDA-approved for weight loss, and ...
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...
In 1985, recombinant human growth hormone was approved for the treatment of children ... of the target population, prompted the FDA to mandate a postmarketing registry to monitor safety.
AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the US Food and Drug ...
The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...
The Food and Drug Administration (FDA) has approved Datroway ® (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results